Atopic Dermatitis

Patients given LNK01001 showed significant improvement in Eczema Area and Severity Index scores over placebo.

Researchers found that 2.4% of the adult UK population had active atopic dermatitis (AD) between 2015 and 2019, the majority of which were mild cases of AD, as only 7.5% to 8.3% of the population had moderate to severe AD.

This review verified past study findings, finding that probiotics can effectively improve atopic dermatitis (AD) in children.

Researchers found that treatment for atopic dermatitis could contribute to a higher mutation rate.

Investigators recommend including domestic violence and abuse as risk factors in public health strategies that target atopic disease assessments.

Outcomes in this new analysis were compared among children aged 6 to 11 years, all of whom had severe atopic dermatitis and were randomized to treatment with dupilumab or placebo for 16 weeks.

This newest analysis on atopic diseases compared outcomes between persons considered to be sexually diverse (lesbian, gay, or bisexual) and heterosexual individuals.

Despite the need for improved eczema therapies and a rapid increase in available clinical trials, participation remains low.

Guidelines for written eczema action plans need to be reviewed for effectiveness before more WAPs are created.

This international study looked at educational outcomes among adolescents with eczema as influenced by their quality of life living with the chronic inflammatory skin condition.

The Revolutionizing Atopic Dermatitis (RAD) meeting took place April 29 through May 1 in Washington, DC, with The American Journal of Managed Care® there to cover the meeting. Some of the top news you may have missed is right below.

Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discusses best practices that physicians and parents of infants with atopic dermatitis (AD) can do to help manage flare- ups, as well as barriers to care, which he presented at the Revolutionizing Atopic Dermatitis conference.

There are recent reports of a potential connection between atopic dermatitis in infants and young children and early exposure to antibiotics and laxatives; however, the totality of the evidence on this link remains lacking.

In a case report, dupilumab and prednisone were among the treatments for atopic dermatitis (AD) used to relieve a patient of her delayed generalized hypersensitivity reaction to the mRNA COVID-19 vaccine.

Experts report that among skin diseases, atopic dermatitis has the lowest reported quality of life.

Patients who have extrinsic (EAD) or intrinsic atopic dermatitis (IAD) serve to benefit equally from dupilumab, even when considering immunoglobulin E levels, which are elevated in EAD but remain normal in IAD.

A recent survey assessed the factors that adult patients with eczema and caregivers find important regarding clinical trial participation decision-making.

Study investigators stress the importance of health care professionals familiarizing themselves with risk factors among a more diverse patient population.

The study findings suggest that treatments for allergic reactions could help decrease the risk of having joint problems.

By better understanding the nature of atopic dermatitis and its varying comorbidities, providers might be able to better predict patient outcomes, said Raj Chovatiya, MD, PhD, assistant professor of dermatology, Northwestern University Feinberg School of Medicine.

Lack of knowledge about how skin conditions present on lightly pigmented skin has resulted in diagnostic delays, underassessment, and an impact on quality of life for patients with skin of color.

Investigators compared outcomes for severe mental illness between patients with both chronic skin conditions and healthy controls, using data from the UK Clinical Practice Research Datalink GOLD.

This study investigated potential benefits of a virtual education intervention for atopic dermatitis that targeted Hispanic Americans and Spanish-speaking populations.

Data from the LIBERTY AD PRESCHOOL trial, and its ongoing open-label extension analysis show that dupilumab is safe and clinically effective, and can lead to statistically significant symptom improvement among patients aged 6 months to 17 years who have moderate to severe atopic dermatitis (AD).

Investigators of this study noted the need for more data on risks of malignancies among patients who have atopic dermatitis (AD), with the chronic skin condition already having significant associations with nonmelanoma skin cancer, lymphoma, keratinocyte carcinoma, and pancreatic and kidney cancers.